Q-omics provides the consensus-scored MRE11 profile across patient tissues and cancer cell-line models. MRE11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRE11 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, MRE11 protein abundance shows 22,561 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where MRE11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRE11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRE11 survival associations across molecular data types. MRE11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRE11 RNA expression–survival associations across cancer types. High MRE11 expression shows unfavorable associations in ACC, LIHC and LGG, but favorable associations in READ, UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRE11 RNA expression.
This table summarizes MRE11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MRE11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRE11 shows higher tumor expression in HNSC, LIHC, BLCA, KIRC, STAD and COAD. The HNSC box plot shows higher MRE11 RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with MRE11 in patient tissues and cancer cell lines. In patient samples, MRE11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MRE11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
